Takeda announced that ORZEYFUL™ (oveporexton) CIV is now available in the U.S. by prescription for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults, bringing the first and only orexin agonist to this community. Learn more at ORZEYFUL.com. “Living with narcolepsy type 1 is an ongoing struggle […]
Tag: narcolepsy
Awakenings from WUN: Making Sense of the Science of Narcolepsy
It’s a very exciting time in narcolepsy research, particularly on two fronts: better understanding the complexities of the disorder and developing more targeted treatments. With so many advances underway, it can feel overwhelming to keep track of research developments and understand how the pieces fit together. This can be especially […]
Alkermes to Present Alixorexton and LUMRYZ Data at Sleep Europe 2026
Alkermes plc announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society’s (ESRS) 28th Congress, Sleep Europe 2026, taking place Oct. 20-23, 2026 in Maastricht, the Netherlands. The company will present new data related to LUMRYZ® […]
Takeda’s ORZEYFUL Launches in Japan and China for Narcolepsy
Takeda announced that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the […]
Zircadia Receives NIH Phase I SBIR Award from NHLBI to Advance In-Ear Sensor for Sleep Diagnostics
We’re happy to announce that we’ve received our Phase I Small Business Innovation Research (SBIR) award from the National Institutes of Health, through the National Heart, Lung, and Blood Institute (NHLBI). This award supports real-world testing of our in-ear sensor system for in-lab and ambulatory sleep monitoring, along with the […]
The Lancet Neurology Publishes Positive Alixorexton Vibrance-1 Data in Narcolepsy Type 1
Alkermes plc announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and […]
ORZEYFUL Approved in Japan for Narcolepsy Type 1 Treatment
Takeda announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat […]
U.S. FDA Approves Takeda’s ORZEYFUL, the First and Only Orexin Agonist for Narcolepsy Type 1
Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. […]
FDA Approves Takeda’s Orzeyful, the First-Ever Orexin Agonist for Narcolepsy Type 1
The U.S. Food and Drug Administration today approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults. Orzeyful is the first medicine approved for narcolepsy type 1 as a complete disorder — addressing the full range of symptoms that define the condition — and the first to […]
Bridging the Communication Gap in Sleep Medicine
In sleep medicine, a profound communication barrier persists: the patient’s lived experience is often lost in translation. While clinicians use precise terms like polysomnogram, patients hear a “sleep study” — or worse, they dismiss lifelong, devastating exhaustion as simply “normal.” In a world where words like tired, fatigued, and sleepy […]


















